(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of -17.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Moderna's revenue in 2023 is $19,263,000,000.On average, 8 Wall Street analysts forecast MRNA's revenue for 2023 to be $4,173,584,136,627, with the lowest MRNA revenue forecast at $1,540,606,398,994, and the highest MRNA revenue forecast at $7,106,894,547,843. On average, 6 Wall Street analysts forecast MRNA's revenue for 2024 to be $2,758,721,230,650, with the lowest MRNA revenue forecast at $1,708,702,756,343, and the highest MRNA revenue forecast at $3,524,255,454,199.
In 2025, MRNA is forecast to generate $5,858,067,263,822 in revenue, with the lowest revenue forecast at $2,313,053,783,237 and the highest revenue forecast at $9,403,080,744,407.